Chembio Starts Distribution of Third-Party COVID-19 Antigen Assay

by Vandana Singh, Benzinga Editor
August 27, 2021 8:34 AM | 1 min read |
  • Chembio Diagnostics Inc CEMI has launched the commercial distribution of an FDA-Emergency Use Authorized rapid point-of-care COVID-19 antigen test. 
  • Product inventory is on-hand and immediately available for shipment to Chembio customers across the U.S.
  • The SCoV-2 Ag Detect Rapid Test, manufactured by InBios International Inc, is a rapid immunoassay test.
  • It provides results in 20 minutes from a nasal swab and requires no instrumentation. 
  • The test can be used for both patients who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset and for asymptomatic serial testing.
  • Related Content: Chembio Q2 Earnings Lag Consensus.
  • Price Action: CEMI shares are up 16.4 at $3.13 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!